1. Community-acquired pneumonia: the evolving challenge
R. Finch 
Clinical Microbiology and Infection 
Volume 7, Pages (January 2001)
DOI: /j s3030.x
Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions

2. Fig 1
Clinical and bacteriological outcome for high-risk subpopulations of patients with community-acquired pneumonia treated with telithromycin 800 mg once daily for 7–10 days. aDocumented pneumococcal bacteremia.
Clinical Microbiology and Infection 2001 7, 30-38DOI: ( /j s3030.x)
Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions

3. Fig 2
Adverse events occuring in > 2% of patients with community-acquired pneumonia treated with telithromycin 800 mg once daily or comparator in controlled trials (modified intent-to-treat population).
Clinical Microbiology and Infection 2001 7, 30-38DOI: ( /j s3030.x)
Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions